Glutamatergic neurotransmission,
depression and antidepressants

by
Ferrero A, Cereseto M.
Farmaceutico, Becario UBA, Junin.
aferrero@ffyb.uba.ar
Vertex. 2004 Jun-Aug;15(56):91-8


ABSTRACT

Depression is a psychiatric disorder that affects 20% of the population. Despite the efforts aimed to identify the mechanisms underlying its behavioral and affective symptoms, no consensus has been reached. In the last years two new theories, the glutamatergic and the genomic ones, have been proposed. Upon the first, the exposition to stressful stimuli increases hippocampal glutamatergic neurotransmission and triggers excitotoxic changes. The second one postulates that depression is closely correlated with neuronal atrophy due to a decrease in BDNF. The aim of this work is to review recent findings about the glutamatergic neurotransmission and its implication in animal models of depression, depressed patients and in both conditions after the antidepressant treatment. We also tried to identify possible links between these observations and the genomic theory.
BDNF
NMDA
Riluzole
Monoamines
21st Century
Noradrenaline
Neurotrophins
NMDA antagonists
New antidepressants
Glutamate and GABA
Antidepressant augmentation strategies


Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family